We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+5.69%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$1.68B
AUM Growth
-$109M
Cap. Flow
-$70.1M
Cap. Flow %
-4.17%
Top 10 Hldgs %
48.34%
Holding
155
New
26
Increased
23
Reduced
13
Closed
37

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$26.4M
2
VTYX
Ventyx Biosciences
VTYX
+$20.8M
3
CBIO
Crescent Biopharma
CBIO
+$19.3M
4
APLS
Apellis Pharmaceuticals
APLS
+$18.3M
5
VRDN icon
Viridian Therapeutics
VRDN
+$16.2M

Top Sells

Rank Stock Value
1
BLU
BELLUS Health Inc.
BLU
+$30.4M
2
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$28.4M
3
ONC
BeOne Medicines Ltd
ONC
+$23.7M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$21.4M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$13.3M

Sector Composition

Rank Sector Weight
1 Healthcare 93.97%
2 Consumer Discretionary 5.18%
3 Financials 0.37%
4 Real Estate 0.31%
5 Technology 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGEM icon
76
Cullinan Oncology
CGEM
$1.06B
$2.56M 0.15%
250,000
– –
ALXO icon
77
ALX Oncology
ALXO
$262M
$2.26M 0.13%
500,000
– –
KRON
78
DELISTED
Kronos Bio
KRON
$2.25M 0.13%
1,542,954
– –
ACHL
79
DELISTED
Achilles Therapeutics
ACHL
$2.16M 0.13%
2,255,375
– –
STOK icon
80
Stoke Therapeutics
STOK
$1.84B
$2.08M 0.12%
250,000
– –
IMUX icon
81
Immunic
IMUX
$178M
$1.9M 0.11%
127,471
– –
GPCR icon
82
Structure Therapeutics
GPCR
$3.37B
$1.78M 0.11%
+75,000
New +$1.76M
TRML
83
DELISTED
Tourmaline Bio
TRML
$1.72M 0.1%
91,426
-115,000
-56% -$1.9M
ME
84
DELISTED
23andMe Holding Co
ME
$1.51M 0.09%
33,050
– –
ADAG
85
Adagene
ADAG
$246M
$1.45M 0.09%
1,000,000
– –
XLO icon
86
Xilio Therapeutics
XLO
$59.8M
$1.43M 0.08%
32,143
– –
HOOK
87
DELISTED
HOOKIPA Pharma
HOOK
$1.36M 0.08%
184,962
– –
CYPH
88
Cypherpunk Technologies Inc
CYPH
$64M
$1.36M 0.08%
400,000
– –
SANA icon
89
Sana Biotechnology
SANA
$882M
$1.31M 0.08%
400,000
– –
CYCN icon
90
Cyclerion Therapeutics
CYCN
$15.2M
$1.21M 0.07%
138,956
– –
IRWD icon
91
Ironwood Pharmaceuticals
IRWD
$586M
$1.16M 0.07%
110,532
– –
TSHA icon
92
Taysha Gene Therapies
TSHA
$1.61B
$1.15M 0.07%
1,440,882
– –
TCRR
93
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$1.13M 0.07%
750,000
– –
SQZ
94
DELISTED
SQZ Biotechnologies Company
SQZ
$900K 0.05%
1,606,309
– –
KNTE
95
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$781K 0.05%
125,000
– –
CRIS icon
96
Curis
CRIS
$9.71M
$775K 0.05%
3,250
– –
HARP
97
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$744K 0.04%
100,000
– –
UTHR icon
98
United Therapeutics
UTHR
$26.1B
$735K 0.04%
+3,281
New +$809K
ARWR icon
99
Arrowhead Research
ARWR
$12.1B
$665K 0.04%
+26,173
New +$823K
BCRX icon
100
BioCryst Pharmaceuticals
BCRX
$2.42B
$566K 0.03%
+67,909
New +$654K
2 3
4
5 6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q1 2023 Portfolio in Review

As of Q1 2023, Artal Group held 155 positions worth $1.68B, down 6.1% from $1.79B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Artal Group withdrew a net $70.1M in Q1 2023, closing 37 positions and reducing 13 holdings. Its most notable exit was BELLUS Health Inc., an estimated $30.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 92% a quarter earlier, followed by Consumer Discretionary and Financials.

Against the trend, Artal Group opened a new position in Ventyx Biosciences worth $17.9M.

  • Artal Group's largest Q1 2023 buy was Ventyx Biosciences: 535,812 shares worth $17.9M.
  • Artal Group added most to Revolution Medicines in Q1 2023, an estimated $26.4M increase.
  • Artal Group's biggest Q1 2023 reduction was Karuna Therapeutics, Inc. Common Stock, cutting an estimated $28.4M.
  • Artal Group fully exited BELLUS Health Inc. in Q1 2023, selling an estimated $30.4M.
  • Artal Group's ten largest holdings make up 48% of its $1.68B portfolio in Q1 2023.
  • Artal Group opened 26 new positions and closed 37 in Q1 2023.
  • Artal Group's portfolio value fell 6.1% quarter-over-quarter to $1.68B.

Based on Artal Group's 13F filing for Q1 2023, filed 12 May 2023.